High-Tech Gründerfonds (HTGF) and private investors in single-cell technology company Cytena have sold all shares to trade buyer Cellink for €30.25m.
Rabobank is to acquire a 34% stake in the healthcare platform via its Corporate Investments arm
Nutrisens management team, led by CEO Georges Devesa, retains a significant stake in the company
Intention to list comes four years after the GP acquired the company via its fourth fund
Online optician has previously received VC funding from investors including Grazia Equity and Goldman Sachs